Analysis of whether Bestivan (Velirivir) is suitable for patients with pancreatic neuroendocrine tumors

Belzutifan (Belzutifan) is an oral small moleculeHIF-2α (hypoxia-induced HIF-2 alpha) inhibitor, mainly regulates tumor hypoxic response and proliferation signals by targeting HIF-2α protein. In the tumor microenvironment, excessive activation of HIF-2α promotes angiogenesis, cell proliferation, and immune evasion, thereby accelerating tumor growth. By inhibitingHIF-2α, bestivan can slow tumor growth and show clinical efficacy in some rare solid tumors. Its mechanism is different from traditional chemotherapy, and it is an innovative method of precise targeted therapy.

Bestivan is currently approved mainly for the treatment of patients with Von and Von Tumors associated with Hippel-Lindau (VHL) disease, including renal cell carcinoma, pancreatic endocrine tumors (pNET), and VHL-related cerebral or retinal hemangiomas. For patients with pancreatic neuroendocrine tumors, especially those with VHL disease-related pNET, abnormal activation of the HIF-2α signaling pathway is often an important driver of tumor proliferation and angiogenesis. Therefore, bezutivan provides a precise treatment option for such patients by targeting this pathway.

Clinical trial data show that besotivan can significantly delay tumor progression in patients with VHL-related pancreatic neuroendocrine tumors, and some patients even achieved partial response (PR) or stable disease (SD). The treatment was generally well tolerated, with the most common adverse reactions including anemia, fatigue, and increased blood pressure, but most were mild to moderate and could be controlled through dose adjustment or symptomatic treatment. This makes bezutivan a potential long-term management option in patients with pancreatic neuroendocrine tumors, especially those who are not candidates for surgery or who have progressive tumor recurrence/span>/.

In general, bezotivan is suitable for patients with VHL related pancreatic neuroendocrine tumors and exerts anti-tumor effects by targeting HIF-2α. Its precise targeting mechanism not only improves the therapeutic effect, but also reduces the risk of systemic side effects of traditional chemotherapy. For VHLpNET in the context of VHLFor patients, Bestivan provides a new treatment option for clinical use, especially showing important value in controlling tumor progression, prolonging progression-free survival and improving patients' quality of life.

Reference materials:https://www.drugs.com/